Usefulness of a New Immunoradiometric Assay of HCV Core Antigen to Predict Virological Response during PEG-IFN/RBV Combination Therapy for Chronic Hepatitis with High Viral Load of Serum HCV RNA Genotype 1b

Intervirology ◽  
2008 ◽  
Vol 51 (1) ◽  
pp. 70-75 ◽  
Author(s):  
Noriko Sasase ◽  
Soo Ryang Kim ◽  
Ke Ih Kim ◽  
Miyuki Taniguchi ◽  
Susumu Imoto ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Combination Therapy ◽  
Virological Response ◽  
High Viral Load ◽  
Core Antigen ◽  
Hcv Rna ◽  
Immunoradiometric Assay ◽  
Hcv Core Antigen ◽  
Genotype 1B

Prolonged Negative HCV-RNA Status Led to a Good Outcome in Chronic Hepatitis C Patients with Genotype 1b and Super-High Viral Load

Intervirology ◽  
2006 ◽  
Vol 49 (6) ◽  
pp. 362-369 ◽  
Author(s):  
Hiroshi Kohno ◽  
Shiomi Aimitsu ◽  
Mikiya Kitamoto ◽  
Yasuyuki Aisaka ◽  
Hiroiku Kawakami ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
High Viral Load ◽  
Hcv Rna ◽  
Good Outcome ◽  
Genotype 1B ◽  
Chronic Hepatitis C Patients

scholarly journals Quantification of Core Antigen Monitors Efficacy of Combination Therapy of Sofosbuvir, Daclatasvir and Ribavirin in Egyptian Cirrhotic Patients with HCV Infection as an Alternative to PCR

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
E H Nashaat ◽  
H Abdel-azziz ◽  
A I Mohammed ◽  
A H Hassan
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Hcv Infection ◽  
Core Antigen ◽  
Hcv Rna ◽  
Major Public Health Problem ◽  
Hcv Core Antigen ◽  
Cirrhotic Patients

Abstract Background Hepatitis C virus (HCV) is a major public health problem throughout the world. Acute HCV infection is asymptomatic in most cases, and only 15% of cases are symptomatic,but Chronic hepatitis C (CHC) shows a variable clinical course, ranging from mild histopathological changes to active hepatitis and the development of hepatic fibrosis, cirrhosis and HCC. The aim of this work is to detect accuracy of core antigen in Egyptian cirrhotic patients with HCV Infection treated with combination therapy of Sofosbuvir, Daclatasvir and Ribavirin as an alternative to PCR. Patients and methods: The study included20 Egyptian treatment-naïve chronic hepatitis C patients with cirrhosis (Cirrhosis was diagnosed on ultrasound basis) on Sofosbuvir, Daclatasvir and Ribavirin. Results Treatment with sofosbuvir plus Daclatasvir and Ribavirin for 12 weeks resulted in undetectable HCV RNA by PCR in 95% (19/20) of the patients at the end of treatment and only 5% (1/20) of the patients achieved SVR after 6 months not 3(both HCV RNA AND HCV Core Antigen tests were negative for all patients). Conclusion: In our study there was a correlation between HCV RNA and HCV core antigen results, so HCV core antigen can be used as an alternative marker to HCV RNA in treatment of HCV infected cirrhotic patients receiving Sofosbuvir, Daclatasvir and Ribavirin.during treatment and for monitoring its efficacy.

Clinical Usefulness of HCV Core Antigen Assay for the Management of Patients with Chronic Hepatitis C

2014 ◽  
Vol 23 (4) ◽  
pp. 393-396 ◽  
Author(s):  
Dragos Florea ◽  
Emil Neaga ◽  
Ionelia Nicolae ◽  
Daniela Maxim ◽  
Madalina Popa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Viral Load ◽  
Tertiary Care ◽  
High Specificity ◽  
Core Antigen ◽  
Hcv Rna ◽  
Test Accuracy ◽  
Molecular Tests ◽  
Hcv Core Antigen ◽  
Using Data

Aim: The study aimed to evaluate the clinical utility of the chemiluminescent HCV core Ag test compared to viral load assessment in the management of patients with chronic hepatitis C.Methods: A retrospective study was performed at a tertiary-care infectious diseases hospital on samples collected from anti-HCV positive patients. Seventy-six samples were tested with the Architect HCV core Antigen kit and Cobas AmpliPrep/Cobas Taqman HCV kit. The HCV Ag test accuracy was estimated using data from all the HCV RNA tested samples received between January 2011 and December 2012.Results: The HCV Ag test showed a good correlation between the logarithmic values of HCV RNA and HCV Ag (R=0.98), with a 100% specificity and PPV, but with reduced sensitivity for viral loads lower than 1,000 UI/ mL. In a model using data from 2,478 HCV RNA tested samples and a cut-off of the Ag assay corresponding to 1,000 UI/mL HCV RNA, the Ag test would have a sensitivity of 82.4%, a NPV of 80.9% and a high specificity and PPV (100%) compared to the viral load. The sensitivity would be higher for baseline evaluation compared to on-treatment samples (98.5 vs. 50%). The highest NPV (98%) would be obtained at 48 and 72 weeks after the initiation of treatment, with a sensitivity of 88.2% and 96.1%, respectively.Conclusion: The Architect HCV core Ag assay might be an alternative for the diagnosis of active HCV infection if molecular tests are not available, and a useful method for the evaluation of sustained virological response in treated patients.

Virological Response in Patients with??Hepatitis C Virus Genotype 1b and??a??High Viral Load

2008 ◽  
Vol 28 (1) ◽  
pp. 9-16 ◽  
Author(s):  
Gotaro Yamada ◽  
Shiro Iino ◽  
Tadao Okuno ◽  
Masao Omata ◽  
Kendo Kiyosawa ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Viral Load ◽  
Hepatitis C ◽  
Virological Response ◽  
High Viral Load ◽  
Virus Genotype ◽  
Genotype 1B
Sign in / Sign up

Export Citation Format

Share Document